Cite
HARVARD Citation
Berger, M. et al. (n.d.). 61PDGenetic variations within the HER3 gene predict outcome for mCRC patients treated with first-line FOLFIRI/bevacizumab or FOLFIRI/cetuximab: Data from FIRE-3. Annals of oncology. p. . [Online].